VTRS
A decent quarter, with a few side quests
Viatris kicked off its second-quarter 2026 update with the kind of headline investors like to see: revenue growth, higher adjusted EBITDA, and a guidance raise. Total revenues came in at $3.8 billion, up 5% year over year on a reported basis, while adjusted EBITDA hit $1.2 billion, up 8% operationally.
The plot twist: less debt, more cash back
The company also said it returned roughly $550 million to shareholders, including share repurchases. In other words, Viatris is doing the classic mature-company balancing act: squeeze out earnings, clean up the balance sheet, and hand some cash back before anyone starts asking too many questions about growth.
It’s also pushing down leverage, with the gross leverage ratio now at 2.9x. That matters because debt levels can be the difference between "steady compounder" and "why is management suddenly sounding very stressed on the earnings call?"
Pipeline breadcrumbs and a little extra spice
Beyond the numbers, Viatris pointed to pipeline progress, including FDA approval of Gwyn Lo and the sale of global rights to Tyrvaya. That combo says the company is still trying to milk value from both new products and asset sales — the corporate equivalent of renovating the kitchen while also listing the guest house.
Big picture: the quarter looked solid enough to support a guidance hike, which is the kind of thing investors usually like to hear unless they were hoping for a bigger surprise.